The omission of radiotherapy (RT) does not affect overall survival at 10 years after breast conserving surgery (BCS) for older women with hormone receptor-positive breast cancer, according to a study that examined the impact of locoregional RT after BCS on long-term outcomes in older patients receiving appropriate systemic therapy. A total of 1,326 patients aged 65 and older with axillary node-negative, hormone receptor-positive breast cancer were randomly assigned to either receive or not receive (658 and 668, respectively) whole breast RT and followed for a median of 7.3 years. At 10 years, ipsilateral breast tumor recurrence rates were 9.8% and 0.9% in the no RT and RT arms, respectively, with a hazard ratio of 0.12 for those receiving RT. Regional recurrence differed significantly (2.3% vs 0.5% with no RT and with RT, respectively), but no differences were seen in contralateral breast cancer or distant metastases. Breast cancer-free survival rates were 12.7% and 6.6% for the no RT and RT arms, respectively. At 10-years, overall survival rates were 80.4% and 81.0% without and with RT, respectively.
Related Posts
Advertisement
Meeting Coverage
- SABCS 2020The 43rd Virtual San Antonio Breast Cancer Symposium (SABCS®) will take place from December 8-11, 2020. The SABCS is the premier conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.